ALEX QIU, Executive Director, Bristol-Myers Squibb

•   Over 30 years’ experience in the oncology field from clinical practice, basic research, preclinical drug discovery, clinical development strategy, and drug safety.

•   20 years pharmaceutical industrial experience ranging from drug discovery, clinical development, pharmacovigilance, and NDA & BLA submission.

•   10 years pharmacovigilance experience, balanced experience for products in the clinical development stage and in the post marketing stage.  Therapeutic area included oncology, autoimmune-diseases, cardiovascular diseases, dermatology, and infectious diseases; as the clinical pharmacology lead or safety lead, led over 25 projects in the clinical development stage ranging from Phase I to phase III, and three post-marketing products (notably, two of them exceeded billion dollars annual revenue, Tarceva and regadenoson).

•   For oncology drug development, indications included and not limited to: None small lung cancer, endometrial cancer, prostate cancer, gastric cancer, pancreatic cancer, head & neck cancer, ovary cancer, HCC, multiple myeloma, AML, CLL, Lymphoma, etc.

•   In term of submission: as lead safety physician: Cilta-cel (Car-T for multiple myeloma) was approved in 2022

•   As the lead safety physician:  Dostarlimab: PD-1 antibody to treat endometrial carcinoma treatment in 2021